Three Menon Biodetectors featured in Pacific Northwest National Laboratory (PNNL) report on Biodetection Technologies for First Responders: 2015 Edition
PNNL has selected all three versions of Menon Biodetectors namely The Lab-in-the-Box, Mini-Mentor and Autonomous MENTOR-100 systems as suitable systems to perform Biodetection in the field by First Responders.
SAN DIEGO, July 1, 2015 – Menon Biosensors, Inc. (MBI) has developed and validated its Autonomous Biodefense systems and assays on autonomous system MENTOR-100, portable miniature system Mini-Mentor and high-throughput Lab-in-the-Box pathogen detector based on its M2 (Molecular Mirroring) nuclear magnetic resonance (NMR) and nanoparticle technology. NMR PlatformTechnology is suitable to perform nucleic acid and immunoassays on a single platform technology.
Recently PNNL has released its 2015 update to its detailed product guide listing biodetection technologies, sampling products and assays. The updated digest provides a comprehensive compilation of commercially available detection devices and products published to help first responders when purchasing equipment and assay kits to rapidly assess biological threats.
The Department of Homeland Security’s Science and Technology Directorate and the Department of Energy’s Pacific Northwest National Laboratory just made the revised report – Biodetection Technologies for First Responders: 2015 – available free of charge. The revised 2015 report can be found in the link below.
This report updates the previous edition, which was downloaded more than 13,000 times.
The Pacific Northwest National Laboratory (PNNL) is working with the U.S. Department of Homeland Security to determine first responder biodetection needs when responding to biological events and to test and evaluate currently available biodetection technologies. As part of this effort, PNNL has been conducting surveys of first responders to improve their understanding of biodetection equipment.
“Menon technology has wide range of applications in biodefense, food and water safety, aquaculture animal healthcare, clinical point-of-care and bio-surveillance by rapidly detecting bacteria, viruses, fungi and parasites while delivering unmatched sensitivity, lowest-cost, fastest detection of nucleic acids compared to most of the nucleic acid methods available today” stated Dr. Suresh Menon, Ph.D., President of Menon Biosensors, Inc. Continued Dr. Menon. “We intend to expand marketing and sales of M² technology for aquaculture worldwide in the coming months.”
About Menon Biosensors’ Platform Technology
M² technology was developed initially to establish rapid countermeasures against bioterrorism. Menon’s technology provides superior results that enable officials to make intelligent, quick decisions following detection and exposure to lethal bacterial agents such as Anthrax (Bacillus anthracis) and Plague (Yersinia pestis). Testing of Menon’s biosensor technology to detect against bioterrorist attack became public information in a press release by the Department of Homeland Security in August 2012.
Menon Biosensors’ M² technology has been validated through multiple studies with the U.S. government’s Biodefense Programs. In these studies, conducted with more than 3,000 samples over a six-year period, the technology demonstrated greater than 99 percent accuracy in the presence of interferants and near neighbors of the pathogens to be detected.
About Menon Biosensors, Inc.
Menon Biosensors is a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens. Menon Biosensors’ microfluidics and M² NMR platform technology (classified by the U.S. Government until 2012) provides superior sensitivity and specificity and minimizes sample preparation, providing best in class sample-to-answer pathogen detection. The technology has been validated by respected third parties in more than 3,000 samples over six years.
858-675-9990 Ext 113